A summary of coverage, coding, and payment for cystic fibrosis carrier screening and diagnostic testing.
A summary of coverage, coding, and payment for molecular cytogenomic testing.
Technology assessment for cytogenomic microarray analysis that evaluates evidence of how this technology improves diagnostic yield and outcomes in patients with developmental delay/mental retardation and autism spectrum disorder.
The most recently approved molecular pathology codes.
Official CMS ruling on Medicare reimbursement for MoPath and other new laboratory testing codes in 2013.
Excerpt from the Social Security Act that describes the gapfilling process.
Excerpt from the Medicare Claims Processing Manual that describes the gapfilling process.
Practice guidelines from ACMG that recommend cytogenomic microarray analysis as a first-line test for postnatal evaluation of individuals with (a) multiple anomalies not specific to a well-delineated genetic syndrome, (b) apparently non-syndromic developmental delay/intellectual disability; or (c) autism spectrum disorders.
Report summarizing a recommendation from the ACMG Cystic Fibrosis Carrier Screening Working Group to (a) remove 1078delT and I148T; and (b) retain R117H in the ACMG CF carrier screening panel.
A technical educational resource for clinical laboratory geneticists that addresses (a) common CFTR mutations associated with racial/ethnic backgrounds, (b) indications for testing, and (c) detailed guidelines on different approaches to CFTR testing.
Current ACOG guidelines for cystic fibrosis carrier screening that recommends offering this test once to all women of reproductive age, among other recommendations.
Illumina is providing this review of the molecular pathology reimbursement landscape in collaboration with Quorum Consulting for educational purposes only. The content should not be considered legal advice. For official ruling on the MoPath codes readers should consult CMS, the AMA, and other sources as appropriate.